BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 19554630)

  • 1. Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgen-dependent murine tumor model.
    Hahn S; Nesslinger NJ; Drapala RJ; Bowden M; Rennie PS; Pai HH; Ludgate C; Nelson BH
    Int J Cancer; 2009 Dec; 125(12):2871-8. PubMed ID: 19554630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins.
    Nickerson T; Miyake H; Gleave ME; Pollak M
    Cancer Res; 1999 Jul; 59(14):3392-5. PubMed ID: 10416600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standard treatments induce antigen-specific immune responses in prostate cancer.
    Nesslinger NJ; Sahota RA; Stone B; Johnson K; Chima N; King C; Rasmussen D; Bishop D; Rennie PS; Gleave M; Blood P; Pai H; Ludgate C; Nelson BH
    Clin Cancer Res; 2007 Mar; 13(5):1493-502. PubMed ID: 17332294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.
    Miyake H; Pollak M; Gleave ME
    Cancer Res; 2000 Jun; 60(11):3058-64. PubMed ID: 10850457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts.
    Schroeder RP; de Visser M; van Weerden WM; de Ridder CM; Reneman S; Melis M; Breeman WA; Krenning EP; de Jong M
    Int J Cancer; 2010 Jun; 126(12):2826-34. PubMed ID: 19876914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.
    Mercader M; Bodner BK; Moser MT; Kwon PS; Park ES; Manecke RG; Ellis TM; Wojcik EM; Yang D; Flanigan RC; Waters WB; Kast WM; Kwon ED
    Proc Natl Acad Sci U S A; 2001 Dec; 98(25):14565-70. PubMed ID: 11734652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.
    Miyake H; Tolcher A; Gleave ME
    Cancer Res; 1999 Aug; 59(16):4030-4. PubMed ID: 10463603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
    Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
    PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumours.
    So AI; Bowden M; Gleave M
    BJU Int; 2004 Apr; 93(6):845-50. PubMed ID: 15050003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent.
    Asamoto M; Hokaiwado N; Cho YM; Takahashi S; Ikeda Y; Imaida K; Shirai T
    Cancer Res; 2001 Jun; 61(12):4693-700. PubMed ID: 11406539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
    Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model.
    Cheng L; Zhang S; Sweeney CJ; Kao C; Gardner TA; Eble JN
    Anticancer Res; 2004; 24(4):2135-40. PubMed ID: 15330153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
    Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
    Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostatic tumor regrowth after initially successful castration therapy may be related to a decreased apoptotic cell death rate.
    Landström M; Damber JE; Bergh A
    Cancer Res; 1994 Aug; 54(16):4281-4. PubMed ID: 7913874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
    Eigl BJ; Eggener SE; Baybik J; Ettinger S; Chi KN; Nelson C; Wang Z; Gleave ME
    Clin Cancer Res; 2005 Jul; 11(13):4905-11. PubMed ID: 16000589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model.
    Gleave ME; Sato N; Goldenberg SL; Stothers L; Bruchovsky N; Sullivan LD
    J Urol; 1997 May; 157(5):1727-30. PubMed ID: 9112514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB; Isaacs JT
    Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.